Immunophenotyping based Oncology Recognition Services
Background Service Workflow Advantages Case Study FAQs
Creative Biolabs offers a suite of immunophenotyping based oncology recognition services to accelerate oncology research, obtain precise cancer cell characterization, develop highly specific biomarkers, and streamline clinical trial processes through advanced flow cytometry, immunohistochemistry, and next-generation sequencing platforms.
Necessity of Immunophenotyping for Oncology Recognition
The precise characterization of cancer cells and their surrounding microenvironment is paramount for effective oncology research and clinical management. Traditional methods often lack the resolution to identify distinct cell populations or subtle changes indicative of disease progression or treatment response. Immunophenotyping fills this critical gap by enabling the detailed analysis of cellular markers. This is crucial for accurate diagnosis, prognostic assessment, and the development of targeted therapies, especially in the evolving landscape of precision oncology and advanced cellular therapies, where understanding cellular identity and function is key to therapeutic success.
Fig.1 Four tumor microenvironmental immunophenotypes depending on driving variables.1
Immunophenotyping based Oncology Recognition Services at Creative Biolabs
Creative Biolabs' comprehensive immunophenotyping based oncology recognition services are designed to provide in-depth cellular analysis, crucial for advancing your oncology projects. We deliver precise identification and quantification of specific cell populations, biomarker profiling, and insights into cellular heterogeneity, all tailored to your research or clinical needs. Our solutions are grounded in robust scientific methodologies, ensuring reliable and actionable data to drive your discoveries forward
Workflow
Upon receipt, samples undergo a rigorous quality assessment, encompassing viability evaluations and cell enumeration. For solid tissue specimens, disaggregation into individual cell suspensions or preparation of tissue sections is subsequently performed.
Our experts collaborate with you to design bespoke multi-parameter antibody panels, selecting fluorochrome-conjugated antibodies or primary/secondary antibody combinations targeting relevant cellular markers. Panels are optimized for specificity and minimal spectral overlap.
Stain prepared samples with tailored antibody panels. For flow cytometry, stained cells are acquired on high-throughput flow cytometers. For immunohistochemistry, stained tissue sections are imaged using advanced microscopy.
The raw data undergoes processing utilizing specialized bioinformatics software. This comprehensive analysis encompasses the implementation of gating strategies pertinent to flow cytometry, quantitative image analysis for immunohistochemistry (IHC), the identification of discrete cellular subsets, and the precise quantification of biomarker expression levels.
A comprehensive report is systematically compiled, meticulously summarizing the methodologies employed, the resultant data, and their interpretations. This compilation incorporates graphical representations of the data, rigorous statistical analyses, and expert commentary elucidating the biological significance of the findings.
Our Service Highlights
-
Highly Precise Cell Characterization
-
Deep Insights into Tumor Heterogeneity and Immune Microenvironment
-
Rapid Turnaround Times
-
Robust Biomarker Discovery and Validation
-
Comprehensive, Actionable Data
Case Study
We use cytometry techniques to examine marker expression in a commercial cohort of seven distinct solid tumor types. This finding indicates an individualized distribution of immune cells in patient-derived samples.
Fig.2 Frequency characterization of immune cell subsets from samples.
FAQs
Q1: What types of samples can Creative Biolabs' Immunophenotyping based Oncology Recognition Services analyze?
A1: Our services are equipped to analyze a comprehensive array of biological specimens, including, but not limited to, peripheral blood, bone marrow aspirates, fresh or formalin-fixed paraffin-embedded (FFPE) tissue biopsies, and various established cell lines. Our expert team is also available to provide guidance on optimal sample collection and preparation protocols to ensure the attainment of superior analytical outcomes for your specific project requirements.
Q2: How do your services help in identifying novel biomarkers for cancer?
A2: Our advanced immunophenotyping platforms, including multi-parameter flow cytometry and high-resolution immunohistochemistry, allow for the simultaneous detection of numerous cell surface and intracellular markers. This comprehensive profiling facilitates the identification of unique cellular signatures associated with disease progression, treatment response, or resistance, thereby aiding in novel biomarker discovery.
Q3: What do clients need to prepare to initiate this project service?
A3: To commence the service, clients are typically requested to provide relevant biological samples, such as fresh or cryopreserved peripheral blood, bone marrow aspirates, tissue biopsies (fresh or FFPE), or established cell lines. Detailed information regarding the sample type, collection methods, and any specific research objectives or desired markers will facilitate the efficient initiation and customization of the service to meet your project's precise requirements.
If you have any questions concerning our services, please do not hesitate to contact us.
Reference
-
Liu, Shaochuan et al. "Novel strategies for cancer immunotherapy: counter-immunoediting therapy." Journal of hematology & oncology vol. 16,1 38. 13 Apr. 2023, doi:10.1186/s13045-023-01430-8. Distributed under Open Access License CC BY 4.0, without modification.
